Reading BMRN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMRN free→Reading BMRN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BMRN free→QuarterlyIQ Insights · BMRN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
The filing describes an amendment to the equity incentive plan, not a management change.
Results of Operations and Financial Condition. On May 4, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its first quarter ended March 31, 2026. The Company’s press release issued on May 4, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…
Entry into a Material Definitive Agreement. The information set forth in
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On the Closing Date, in connection with the Merger, the Company entered into a Credit Agreement (the “ Credit Agreement ”), by and among the Company, as borrower, the lenders and issuing banks from time to time party thereto, and Citibank, N.A., as administrative agent and collateral agent (in such capacities, the “ Administrative Agent ” and the “ Collateral Agent ,” respectivel…
by reference. At the effective time of the Merger (the “ Effective Time ”), each share of common stock, par value $0.01 per share, of Amicus (“ Amicus Common Stock ”) issued and outstanding immediately prior to the Effective Time (other than certain excluded shares as described in the Merger Agreement) was automatically cancelled and converted into the right to receive $14.50 in cash, without interest thereon and subject to any applicable withholding of taxes. Pursuant to the Merger Agreement…
Other Events. As previously disclosed, on December 19, 2025, BioMarin Pharmaceutical Inc. (“ BioMarin ”) and Lynx Merger Sub 1, Inc., a wholly owned subsidiary of BioMarin (“ Merger Sub ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Amicus Therapeutics, Inc. (“ Amicus ”), providing for the merger of Merger Sub with and into Amicus (the “ Merger ”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin. On April 23, 2026, the Ministry of Eco…
Results of Operations and Financial Condition. On February 23, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its fourth quarter ended December 31, 2025. The Company’s press release issued on February 23, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Excha…
Entry into a Material Definitive Agreement. On February 12, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) completed its previously-announced private placement of $850 million aggregate principal amount of 5.500% Senior Notes due 2026 (the Notes) to several investment banks acting as initial purchasers who subsequently resold the Notes to qualified institutional buyers as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and outside the Unite…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in
Regulation FD Disclosure. On January 29, 2026, BioMarin Pharmaceutical Inc. (BioMarin or the company) entered into a purchase agreement (the Purchase Agreement) with Morgan Stanley & Co. LLC as representative of the several initial purchasers listed in Schedule I thereto (collectively, the Initial Purchasers), relating to the sale by BioMarin of $850 million of 5.500% senior unsecured notes due 2034 (the Notes) in a private placement to qualified institutional buyers pursuant to Rule 144A und…
Results of Operations and Financial Condition. E stimated Third Quarter 2025 Acquired In-Process Research and Development (IPR&D) Charges In connection with its previously announced acquisition of Inozyme Pharma, Inc. on July 1, 2025, BioMarin Pharmaceutical Inc. (BioMarin) expects that its reported financial results calculated in accordance with U.S. generally accepted accounting principles (GAAP) and its Non-GAAP financial results for the third quarter of 2025 will include acquired IPR&D ch…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.